In the race to make the most tolerable obesity drug, there seems to be no clear winner—at least not according to analysts ...

It would behoove more Americans to learn how consistent seafood consumption has strong potential to ward off coronary disease ...

Eli Lilly’s first quarter saw rapid revenue growth, but the market responded negatively due to profit shortfalls and emerging ...

The GLP-1 Exit Plan by Holli Bradish-Lane Holli Bradish-Lane, founder of Iron Crucible Health Coaching, is making waves in ...

GLP-1 obesity drug use is rising, but long-term adherence remains low. While one-year persistence has improved in 2024, only ...

Eli Lilly, Novo Nordisk and Amgen release weight loss drug data as competition heats up in the market, while Abridge ...

Full Phase 2 study results showed side effects that led people to stop treatment with MariTide, as well as weight loss ...

Hims & Hers Health Inc.'s stock booked record losses Monday after pharmaceutical giant Novo Nordisk, maker of the weight-loss drug Wegovy, said it was ending a collaboration with the telehealth ...

Q: My doctor is suggesting that I try taking one of those new weight loss drugs -- off-label -- to help me cut down on my alcohol consumption. Does this make any sense? -- Pat R., Ann Arbor, Michigan ...

Some new medications in development are also trying to solve for a persistent side effect of existing drugs: Patients who ...

The shipments have vaulted Ireland, a country of only five million people, into the second-largest goods-trade imbalance with ...

A new obesity drug combining four hormones may outperform Wegovy and Mounjaro. Learn what it means for health, science, and investors.